# A Study Evaluating Drug-Drug Interaction (DDI) Between HSK3486 Injectable Emulsion and Rifampin Capsules

> **NCT03758469** · PHASE1 · COMPLETED · sponsor: **Sichuan Haisco Pharmaceutical Group Co., Ltd** · enrollment: 16 (actual)

## Conditions studied

- Anesthesia
- Sedation

## Interventions

- **DRUG:** HSK3486
- **DRUG:** rifampin , HSK3486

## Key facts

- **NCT ID:** NCT03758469
- **Lead sponsor:** Sichuan Haisco Pharmaceutical Group Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-12-14
- **Primary completion:** 2019-01-31
- **Final completion:** 2019-03-10
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2019-08-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03758469

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03758469, "A Study Evaluating Drug-Drug Interaction (DDI) Between HSK3486 Injectable Emulsion and Rifampin Capsules". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03758469. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*